ARS Pharmaceuticals, Inc.
SPRYNext catalyst
epinephrine
Urticaria Chronic
Get an email about SPRY's next catalysts
Track ARS Pharmaceuticals (SPRY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
epinephrine Phase 2 Est. Readout
Estimated primary completion for epinephrine trial (NCT06927999) in Urticaria Chronic. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ARS-1 | Phase 2 | Asthma | - | - |
epinephrine | Phase 2 | Urticaria Chronic | - | - |
Albuterol MDI | Phase 2 | Asthma | - | - |
Frequently asked questions
What is in ARS Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ARS Pharmaceuticals, Inc.'s (SPRY) pipeline across Phase 2. Its lead program is epinephrine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ARS Pharmaceuticals, Inc.'s next FDA catalyst?→
ARS Pharmaceuticals, Inc.'s (SPRY) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SPRY biotech catalysts?→
Add SPRY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ARS Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.